Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXHALE-3
2023-503693-20-01Phase 3Completed
- Sponsor
- Areteia Therapeutics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Dexpramipexole with Placebo (2 arms). Primary endpoint: Annualized rate of severe asthma exacerbations (AAER) over 52 weeks. Started Mar 2024; status: completed.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2023-503693-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503693-20-01.